4.7 Article

Maintenance of Sinus Rhythm and Survival in Patients With Heart Failure and Atrial Fibrillation

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 55, Issue 17, Pages 1796-1802

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2010.01.023

Keywords

antiarrhythmia agents; anticoagulants; atrial fibrillation; congestive heart failure

Funding

  1. Medtronic
  2. Boehringer Ingelheim
  3. Sanofi-Aventis
  4. Bristol-Myers Squibb
  5. Servier
  6. Cardiome
  7. Aryx
  8. Biosense-Webste
  9. Sanofi
  10. St. Jude Medical
  11. Biosense-Webster
  12. AstraZeneca
  13. CardioInsight
  14. Biotronik
  15. Daiichi Sankyo
  16. Ablation Frontiers
  17. GlaxoSmithKline
  18. CV Therapeutics
  19. Sequel Pharmaceuticals

Ask authors/readers for more resources

Objectives The goal of this study was to evaluate the relationship between the presence of sinus rhythm and outcomes in patients with a history of congestive heart failure (CHF) and atrial fibrillation (AF). Background The value of sinus rhythm maintenance in patients with AF and heart failure (HF) is uncertain. Methods A total of 1,376 patients with AF, ejection fraction <= 35%, and heart failure symptoms were randomized to a rhythm-or rate-control strategy. Detailed efficacy analyses were used to evaluate the independent effects of treatment strategy and the presence of sinus rhythm on cardiovascular outcomes. Results Overall, 445 (32%) patients died and 402 (29%) experienced worsening HF. The rhythm-control strategy was not predictive of cardiovascular mortality (hazard ratio [HR]: 0.90, 95% confidence interval [CI]: 0.70 to 1.16; p = 0.41), all-cause death (HR: 0.86, 95% CI: 0.69 to 1.08; p = 0.19), or worsening HF (HR: 0.86, 95% CI: 0.68 to 1.10; p = 0.23). In analyses devised to isolate the effect of underlying rhythm, sinus rhythm was not associated with cardiovascular mortality [HR: 1.22, 95% CI: 0.80 to 1.87; p = 0.35), total mortality [HR: 1.11, 95% CI: 0.78 to 1.58; p = 0.57), or worsening HF [HR: 0.62, 95% CI: 0.37 to 1.02; p = 0.059). Conclusions A rhythm-control strategy or the presence of sinus rhythm are not associated with better outcomes in patients with AF and CHF. (J Am Coll Cardiol 2010; 55: 1796-802) (C) 2010 by the American College of Cardiology Foundation

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available